A preview of a clinical trial update about a novel bispecific retinal therapy for diabetic macular edema, highlighting trial scope and intent.
Key Takeaways
- Precommercial retina-focused biotechnology company committed to researching
- "Anti-VEGF therapies have transformed the treatment of DME
- VEGF is an established driver of vascular permeability and abnormal vessel growth in retinal vascular disease